Welcome to today's episode, where we dive into a monumental breakthrough in oncology, i.e., cracking the "undruggable" KRAS mutation. For decades, pancreatic cancer has been notoriously lethal, with few treatment options. Enter daraxonrasib (RMC-6236), a revolutionary "molecular glue" that targets the active "ON" state of mutated RAS proteins. In the recent Phase 3 RASolute 302 trial, this targeted therapy nearly doubled overall survival for metastatic pancreatic cancer patients compared to standard chemotherapy, extending it to 13.2 months. Join us as we explore the structural biology behind this tri-complex inhibitor, its unique resistance profile, and the future of precision cancer therapy. Produced by Dr. Jake Chen.
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
Get summaries like this every morning.
Free AI-powered recaps of Drug Discovery AI Talk and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.